TOP TEN perturbations for 38549_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38549_at
Selected probe(set): 213797_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38549_at (213797_at) across 6674 perturbations tested by GENEVESTIGATOR:
T. cruzi study 1 (VSMC; 48h) / mock infected vascular smooth muscle cell sample (48h)
Relative Expression (log2-ratio):9.13413Number of Samples:3 / 3
| Experimental | T. cruzi study 1 (VSMC; 48h) |
| Human vascular smooth muscle cells (VSMCs) infected with Trypanosoma cruzi trypomastigotes for 2 hours (10exp8/ml) and harvested 48 hours post infection. Cells were maintained in Ham’s F12K medium with 2 mM L-glutamine, 1.5 g/L sodium bicarbonate, 10 mM HEPES, 10 mM TES, 0.05 mg/ml ascorbic acid, 0.001 mg/ml insulin, 0.01 mg/ml transferrin, 10ng/ml sodium selenite, 0.03 mg/ml endothelial cell growth supplement (ECGS) and 10% FBS. | |
| Control | mock infected vascular smooth muscle cell sample (48h) |
| Human vascular smooth muscle cells (VSMCs) mock-infected and harvested 48 hours post mock infection with 2% FBS medium. Cells were maintained in Ham’s F12K medium with 2 mM L-glutamine, 1.5 g/L sodium bicarbonate, 10 mM HEPES, 10 mM TES, 0.05 mg/ml ascorbic acid, 0.001 mg/ml insulin, 0.01 mg/ml transferrin, 10ng/ml sodium selenite, 0.03 mg/ml endothelial cell growth supplement (ECGS) and 10% FBS. |
polyinosinic-polycytidylic acid study 1 (10ug/ml) / vehicle (DME) treated bronchial epithelial cell sample
Relative Expression (log2-ratio):8.611983Number of Samples:3 / 17
| Experimental | polyinosinic-polycytidylic acid study 1 (10ug/ml) |
| Bronchial epithelial cells (NHBE) treated with polyinosinic-polycytidylic acid (Poly(I:C); 10ug/ml; vendor: InvivoGen / catalog number: tlrl-pic / catalog name: Poly(I:C) High Molecular Weight [31852-29-6]) for 6 hours. For treatment primary cells were seeded at a density of 50'000 cells/well in pre-coated rat tail collagen type I 96-well plates for 24 hours followed by 4 hours starvation. NHBE cells were isolated from different Caucasian, healthy and non-smoker donors from the airway located above the bifurcation of the lungs (tracheal/bronchial). ATC code: | |
| Control | vehicle (DME) treated bronchial epithelial cell sample |
| Bronchial epithelial cells (NHBE) treated with vehicle (DME) for 6 hours. For treatment primary cells were seeded at a density of 50'000 cells/well in pre-coated rat tail collagen type I 96-well plates for 24 hours followed by 4 hours starvation. NHBE cells were isolated from different Caucasian, healthy and non-smoker donors from the airway located above the bifurcation of the lungs (tracheal/bronchial). |
T. cruzi study 1 (BJ; 24h; bottom) / mock infected foreskin fibroblast (BJ) sample (24h; bottom)
Relative Expression (log2-ratio):8.168603Number of Samples:2 / 2
| Experimental | T. cruzi study 1 (BJ; 24h; bottom) |
| Foreskin fibroblast (BJ) cells grown in the transwell bottom, infected with Trypanosoma cruzi trypomastigotes for 2 hours (10exp8/ml) and harvested 24 hours post infection. Cells were maintained in DMEM supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, 100 U/ml penicillin and 100 ug/ml streptomycin. | |
| Control | mock infected foreskin fibroblast (BJ) sample (24h; bottom) |
| Foreskin fibroblast (BJ) cells grown in the transwell bottom, mock-infected and harvested 24 hours post mock infection with 2% FBS medium. Cells were maintained in DMEM supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, 100 U/ml penicillin and 100 ug/ml streptomycin. |
T. cruzi study 1 (HMVEC; 24h; bottom) / mock infected cardiac microvascular endothelial cell sample (24h; bottom)
Relative Expression (log2-ratio):8.029409Number of Samples:2 / 2
| Experimental | T. cruzi study 1 (HMVEC; 24h; bottom) |
| Human cardiac microvascular endothelial cells (HMVECs) grown in the transwell bottom, infected with Trypanosoma cruzi trypomastigotes for 2 hours (10exp8/ml) and harvested 24 hours post infection. Cells were maintained in endothelial cell basal medium-2 and endothelial cell growth supplements including 5% FBS. | |
| Control | mock infected cardiac microvascular endothelial cell sample (24h; bottom) |
| Human cardiac microvascular endothelial cells (HMVECs) grown in the transwell bottom, mock-infected and harvested 24 hours post mock infection with 2% FBS medium. Cells were maintained in endothelial cell basal medium-2 and endothelial cell growth supplements including 5% FBS. |
T. cruzi study 1 (HMVEC; 24h; top) / mock infected cardiac microvascular endothelial cell sample (24h; top)
Relative Expression (log2-ratio):7.703745Number of Samples:2 / 2
| Experimental | T. cruzi study 1 (HMVEC; 24h; top) |
| Human cardiac microvascular endothelial cells (HMVECs) grown in the transwell top, bathed with media from the HMVECs infected with Trypanosoma cruzi trypomastigotes for 2 hours (10exp8/ml) and harvested 24 hours post infection. In the transwell setup, cells in the top chamber served as reporters for the effect of all difusible factors secreted by parasite-infected cells in the bottom chamber. Cells were maintained in endothelial cell basal medium-2 and endothelial cell growth supplements including 5% FBS. | |
| Control | mock infected cardiac microvascular endothelial cell sample (24h; top) |
| Human cardiac microvascular endothelial cells (HMVECs) grown in the transwell top, bathed with media from the mock-infected bottom HMVECs, harvested 24 hours post mock infection with 2% FBS medium. In the transwell setup, cells in the top chamber served as reporters for the effect of all difusible factors secreted by mock-infected cells in the bottom chamber. Cells were maintained in endothelial cell basal medium-2 and endothelial cell growth supplements including 5% FBS. |
HIVGFP(G); SIVVLP(G) study 1 / uninfected monocyte-derived dendritic cell sample
Relative Expression (log2-ratio):7.3986053Number of Samples:2 / 2
| Experimental | HIVGFP(G); SIVVLP(G) study 1 |
| Monocyte-derived dendritic cell samples (MDDC) from isolated and stimulated CD14+ monocytes (GM-CSF and IL-4 for dendritic cell differentiation) of adult peripheral blood. MDDC were infected with GFP-encoding HIV-1 pseudotyped with VSV-G [HIVGFP(G)] and VSV-G-pseudotyped SIVmac239 virus-like particles [SIVVLP(G)] for 48 hours. | |
| Control | uninfected monocyte-derived dendritic cell sample |
| Monocyte-derived dendritic cell samples (MDDC) from isolated and stimulated CD14+ monocytes (GM-CSF and IL-4 for dendritic cell differentiation) of adult peripheral blood. MDDC were treated with lipopolysaccharide (LPS) for 48 hours. |
smoking study 81 (CSE) / human rhinovirus study 3
Relative Expression (log2-ratio):-7.2901726Number of Samples:4 / 4
| Experimental | smoking study 81 (CSE) |
| Human bronchial epithelial (HBE) cells isolated from non-smoking individuals and subjected to a treatment with 50% cigarette smoke extract (CSE) for 24 hours. In order to prepare CSE, one reference cigarette 3R4F was bubbled into 4 ml of hydrocortisone-free bronchial epithelial cell growth medium (BEGM) for 5 minutes using a syringe apparatus. Absorbance of the obtained CSE was adjusted to 0.15 at 320 nm and the resulting CSE was used at 50% concentration. HBE cells were isolated by protease digestion of dissected airways and grown in BEGM. HBE cells were cultured in hydrocortisne-free BEGM overnight before the CSE stimulation. Cells were isolated from subjects that died from cerebrovascular causes or accidental head trauma, and had negative serologies for HIV1/2, HTLV1/2, hepatitis A, B and C, and syphilis. | |
| Control | human rhinovirus study 3 |
| Human bronchial epithelial (HBE) cells isolated from non-smoking individuals and subjected to an infection with human rhinovirus 16 (HRV-16; MOI=1) for 24 hours. HBE cells were isolated by protease digestion of dissected airways and grown in BEGM. HBE cells were cultured in hydrocortisne-free BEGM overnight before the HRV-16 infection. Cells were isolated from subjects that died from cerebrovascular causes or accidental head trauma, and had negative serologies for HIV1/2, HTLV1/2, hepatitis A, B and C, and syphilis. |
interferon-alpha-A/D study 1 (early) / untreated BE(2)-C cell sample (mature)
Relative Expression (log2-ratio):7.238248Number of Samples:3 / 3
| Experimental | interferon-alpha-A/D study 1 (early) |
| Cultured BE(2)-C cells were differentiated with 10 uM all-trans retinoic acid (RA) for 3 weeks into cells with mature neuron cell characteristics and incubated with universal type I IFN (IFN-alpha-A/D) for 6 hours before samples were taken. ATC code:--- | |
| Control | untreated BE(2)-C cell sample (mature) |
| Differentiated, cultured BE(2)-C neuroblastoma cells. Cells were differentiated with 10 uM all-trans retinoic acid (RA) for 3 weeks into cells with mature neuron cell characteristics before samples were taken. |
HIVGFP(G); SIVVLP(G) study 1 / HIVGFP(G) study 1
Relative Expression (log2-ratio):7.1963177Number of Samples:2 / 2
| Experimental | HIVGFP(G); SIVVLP(G) study 1 |
| Monocyte-derived dendritic cell samples (MDDC) from isolated and stimulated CD14+ monocytes (GM-CSF and IL-4 for dendritic cell differentiation) of adult peripheral blood. MDDC were infected with GFP-encoding HIV-1 pseudotyped with VSV-G [HIVGFP(G)] and VSV-G-pseudotyped SIVmac239 virus-like particles [SIVVLP(G)] for 48 hours. | |
| Control | HIVGFP(G) study 1 |
| Monocyte-derived dendritic cell samples (MDDC) from isolated and stimulated CD14+ monocytes (GM-CSF and IL-4 for dendritic cell differentiation) of adult peripheral blood. MDDC were infected with GFP-encoding HIV-1 pseudotyped with VSV-G [HIVGFP(G)] for 48 hours. |
LPS study 1 / vehicle (DTT/polym. B) treated monocyte sample
Relative Expression (log2-ratio):7.1394815Number of Samples:3 / 3
| Experimental | LPS study 1 |
| Monocytes were plated in 12-well plates and differentiated in RPMI 1640 containing 10% FBS plus 50 ng/ml (>500 U/ml) GM-CSF and 100 ng/ml (>500 U/ml) IL-4 for 5 days. At day 5, Lipopolysaccharide (LPS; 100 ng/ml) was added. At 18 h after treatment, total RNA was isolated. ATC code:--- | |
| Control | vehicle (DTT/polym. B) treated monocyte sample |
| Monocytes were plated in 12-well plates and differentiated in RPMI 1640 containing 10% FBS plus 50 ng/ml (>500 U/ml) GM-CSF and 100 ng/ml (>500 U/ml) IL-4 for 5 days. At day 5, vehicle consisting of equivalent volume of 8 mM DTT (galectin-1 storage buffer) and 10 μg/ml polymyxin B was added. At 18 h after treatment, total RNA was isolated. |